Roche Holding AG (OTCMKTS:RHHBY) Receives Consensus Recommendation of “Reduce” from Brokerages

Shares of Roche Holding AG (OTCMKTS:RHHBY) have earned an average recommendation of “Reduce” from the six research firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $40.00.

RHHBY has been the subject of several research reports. The Goldman Sachs Group initiated coverage on Roche in a report on Thursday, May 30th. They set a “sell” rating for the company. Deutsche Bank Aktiengesellschaft raised shares of Roche from a “sell” rating to a “hold” rating in a report on Friday, May 17th.

Roche Stock Performance

Shares of RHHBY stock opened at $41.16 on Wednesday. Roche has a 52 week low of $29.20 and a 52 week high of $42.43. The firm’s 50-day simple moving average is $38.78 and its two-hundred day simple moving average is $34.47. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.75.

Institutional Investors Weigh In On Roche

Institutional investors have recently made changes to their positions in the business. Cardinal Capital Management Inc. bought a new position in Roche during the 2nd quarter worth approximately $16,860,000. Saratoga Research & Investment Management grew its holdings in shares of Roche by 6.9% in the first quarter. Saratoga Research & Investment Management now owns 2,458,918 shares of the company’s stock worth $78,489,000 after purchasing an additional 158,482 shares during the last quarter. Meritage Portfolio Management increased its stake in shares of Roche by 186.9% in the first quarter. Meritage Portfolio Management now owns 174,714 shares of the company’s stock worth $5,577,000 after buying an additional 113,823 shares during the period. Hantz Financial Services Inc. bought a new stake in Roche during the 2nd quarter valued at $1,164,000. Finally, ORG Partners LLC purchased a new stake in Roche during the 1st quarter valued at $689,000.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.